A dozen years of clinical trials performing advanced cell therapy with perinatal cells

What is it about?

This editorial is a follow-on to our review of regenerative medicine clinical trials with perinatal cells for the decade 2005 - 2015. Now we add two more years of data and review the dozen years 2005 - 2017.

Featured Image

Why is it important?

First, the trends identified in our original 10-year review have continued: The number of clinical trials using cord blood cells for advanced cell therapy are within the same range year after year, whereas trials using other perinatal cells for regenerative medicine are increasing by 20% per year on average. In addition, we now find that perinatal mesenchymal stromal cells (MSC) have become the dominant source of all MSC trials during the years 2016 and 2017.